Abstract:The last step in influenza virus replication involves the assembly of viral components on the infected cell's plasma membrane followed by budding of intact virus from the host cell surface. Because viral neuraminidase and hemagglutinin are both inserted into the host cell's membrane during this process, influenza virus-infected cells are distinguished from uninfected cells by the presence of viral neuraminidase and hemagglutinin on their cell surfaces. In an effort to exploit this difference in cell surface markers for development of diagnostic and therapeutic agents, we have modified an influenza neuraminidase inhibitor, zanamivir, for targeting of attached imaging and therapeutic agents selectively to influenza viruses and virus-infected cells. We have designed here a zanamivir-conjugated rhodamine dye that allows visual monitoring of binding, internalization, and intracellular trafficking of the fluorescence-labeled neuraminidase in virus-infected cells. We also synthesize a zanamivir-<sup>99m</sup>Tc radioimaging conjugate that permits whole body imaging of the virus's biodistribution and abundance in infected mice. Finally, we create both a zanamivir-targeted cytotoxic drug (i.e., zanamivir-tubulysin B) and a viral neuraminidase-targeted CAR T cell and demonstrate that they are both able to kill viral neuraminidase-expressing cells without damaging healthy cells. Taken together, these data suggest that the influenza virus neuraminidase inhibitor, zanamivir, can be exploited to improve the diagnosis, imaging, and treatment of influenza virus infections.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.bioconjchem.1c00255?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.bioconjchem.1c00255</a>.Experimental details, materials, and methods, including the spectra of the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.bioconjchem.1c00255/suppl_file/bc1c00255_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Multivalent Neuraminidase Hydrolysis Resistant Triazole-Sialoside Protein Conjugates As Influenza-Adsorbents

Multivalent S-sialoside Protein Conjugates Block Influenza Hemagglutinin and Neuraminidase.

Preparation of Eicosavalent Triazolylsialoside-Conjugated Human Serum Albumin As a Dual Hemagglutinin/neuraminidase Inhibitor and Virion Adsorbent for the Prevention of Influenza Infection

Amide-sialoside Protein Conjugates As Neomucin Bioshields Prevent Influenza Virus Infection.

Synthetic pentatrideca-valent triazolylsialoside inhibits influenza virus hemagglutinin/neuraminidase and aggregates virion particles

A Zanamivir-protein conjugate mimicking mucin for trapping influenza virion particles and inhibiting neuraminidase activity

Multivalent Interactions Between Fully Glycosylated Influenza Virus Hemagglutinins Mediated by Glycans at Distinct N-glycosylation Sites

Multivalent Oleanolic Acid Human Serum Albumin Conjugate As Nonglycosylated Neomucin for Influenza Virus Capture and Entry Inhibition.

Guanidinothiosialoside-Human Serum Albumin Conjugate Mimics mucin Barrier to Restrict Influenza Infection

Synthesis and In Vitro Anti-Influenza Virus Evaluation of Novel Sialic Acid (C-5 and C-9)-Pentacyclic Triterpene Derivatives

Glycopolymer with Sulfated Fucose and 6'-Sialyllactose as a Dual-Targeted Inhibitor on Resistant Influenza A Virus Strains

Design, Synthesis And Biological Activity Evaluation Of Novel Conjugated Sialic Acid And Pentacyclic Triterpene Derivatives As Anti-Influenza Entry Inhibitors

Synthesis of multivalent sialyllactose-conjugated PAMAM dendrimers: Binding to SARS-CoV-2 spike protein and influenza hemagglutinin

Synthesis of Novel Pentacyclic Triterpene-Neu5ac2en Derivatives and Investigation of Their in Vitro Anti-Influenza Entry Activity.

Trivalent oleanolic acid-glucose conjugates: Synthesis and efficacy against Influenza A virus

Design, Synthesis and Biological Evaluation of Amino Acids-Oleanolic Acid Conjugates As Influenza Virus Inhibitors.

Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections

Novel mono- and multivalent N -acetylneuraminic acid glycoclusters as potential broad-spectrum entry inhibitors for influenza and coronavirus infection

Assembly of Poly(ethylene Glycol)ylated Oleanolic Acid on a Linear Polymer As a Pseudomucin for Influenza Virus Inhibition and Adsorption.

Synthesis of a Hexavalent Betulinic Acid Derivative as a Hemagglutinin-Targeted Influenza Virus Entry Inhibitor

Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity